Wednesday, 7 June 2017

AstraZeneca sells migraine drug for up to $302 million

LONDON (Reuters) - AstraZeneca continued its program of divesting old medicines on Wednesday with the sale for up to $302 million of migraine drug Zomig to Germany's Grunenthal.


No comments:

Post a Comment